Recommended Global Pharmaceutical Sciences Conferences
- About Antimicrobials 2020
- Antimicrobials 2020 Sessions And Tracks
- Antimicrobials 2020 Market Analysis
- Past Conference Report
About Antimicrobials 2020
Antimicrobials 2020 is a stage to examine and find out about the most recent progresses in the field of Antibiotics and Antibiotic Resistance as the world's thought turned with respect to the anxiety of new anti-toxins as the antimicrobial resistance is developing step by step. Numerous countries and International wellbeing associations are undertaking to focal point of the present circumstance and making new strategies to prevent the adverse effects of Antibiotic resistance.
Why to attend:
Antimicrobials 2020 is an international stage for presenting researches about antibiotics, bacterial infections and exchanging ideas, contributes to the dissemination of knowledge in Antibiotics, Antimicrobials and Antibiotics Resistance for the advantage for both the academic and business.
The organizing committee of this Antimicrobial Conference is gearing up for inspiring and explanatory conference program including Keynote talks, workshops on a variety of topics, poster presentations and various programs for participants from all over the globe. We invite you to join us at the Antimicrobials 2020, where you will be sure to have a meaningful experience with scholars from all around the world. All members of the Antimicrobials 2019 Conference and Organizing Committee look forward to meeting you in Singapore.
- Food Safety Experts
- Alliances of antibiotics
- Business Entrepreneurs
- Antibiotics Researchers
- Strategic Drug Development
- Executive Council of Global
- Directors of Pharma Industries
- Medical Affairs and Networking
- Public Health Preparedness Sectors
- Scientific Business Communications
- Antibiotics Associations & Societies
- Associate Professors
- Medical companies
- Pharmaceutical companies
Importance & Scope:
Antimicrobials 2020 highlights the theme “Innovative and Approaches in the field of Antibiotics and Antimicrobials”. Antimicrobials 2020 is an event designed in a way to provide an exclusive platform for upcoming researchers, scientists, students and educators to present and discuss the latest innovations, trends, and concerns, practical challenges encountered and the solutions adopted in the microbiology field. The two days of educational program will include keynote talks, session speakers, and poster presenters on the latest in innovative technologies as well as papers in the areas of Antimicrobials conferences, Antibiotic conferences, Antibiotic Resistance conferences, workshops on the field of microbiology.
Antimicrobials 2020 Sessions And Tracks
The scientific invention is a major rock for global medical service which includes both academic and industrial research. The drug discovery process involves both academic and industrial innovations. The drug development process is as follows: inventing or discovering a compound, preclinical trials on microbes and animals i.e., in-vitro, in-vivo, clinical trials involving patients by clinical research management. Social responsibility and ethics should walk hand in hand with research for good clinical research management.
Track 2: Antibiotics by Drug origin
The first economically available antibacterial was Prontosil, a sulfonamide improved by the German biochemist Gerhard Domagk in the 1930s. Before this, in 1928, Alexander Fleming had invented the first antibiotic, penicillin, but it took over a decade before penicillin was introduced as a treatment for bacterial infections. This was possible through the work of Florey and Chain who managed to purify the antibiotic and scale-up production efficiently. The introduction of penicillin considered the beginning of the so-called “golden era” of antibiotics. Between 1940 and 1962, most of the antibiotic classes we use as medicines today were invented and recommended to the market. Each class typically consists of several antibiotics that have been discovered over time or are modified versions of previous types. Such as different penicillins and cephalosporins.
Environmental microbes are a leading source of drug discovery, and several microbial products ( anti-tumor products, antibiotics, immunosuppressants and others) are used frequently for human therapies. Most of these products were accessed from cultivable (<1%) environmental microbes, means that a large number of microbes were not targeted for drug discovery. With the onset of new and emerging technologies, we are poised to harvest novel drugs from the so-called 'uncultivable' microbes. Multidisciplinary ways of linking different technologies can assist and reform drug discovery from uncultivable microbes and inspect the current cramp of technologies and scenarios to swamped such constraints that might further expand the promise of drugs from environmental microbes.
Antibiotics are used to treat or prevent bacterial infections and consistently protozoan infections. (Metronidazole is efficient against a number of parasitic diseases). When an infection is suspected of being responsible for an illness but the responsible pathogen has not been identified, empiric therapy is adopted. This involves the application of a broad-spectrum antibiotic occupying on the signs and a symptom presented and is initiated pending laboratory results that can take a lot of days.
Less common side effects of antibiotics include:
- formation of kidney stones, when taking sulphonamides
- abnormal blood clotting, when taking some cephalosporin
- sensitivity to sunlight, when taking tetracycline
- blood disorders, when taking trimethoprim
- deafness, when taking erythromycin and the aminoglycosides
Antibiotics are not the right choice for all infections. For example, most sore throats, cough and colds, flu or acute sinusitis are viral in origin (not bacterial) and do not require an antibiotic. These viral infections are “self-limiting”, meaning that your own immune system will commonly kick in and fight the virus off. In fact, using antibiotics for viral infections can raise the risk for antibiotic resistance, lower the options for future treatments if an antibiotic is needed, and put a patient at risk for side effects and extra cost due to irrelevant drug treatment.
Track 6: Antibiotics and their interactions
An antibiotic is a nature of antimicrobial phenomenon effective against bacteria and is the most important category of antibacterial agents for fighting bacterial infections. Antibiotic medications are generally used in the treatment and prevention of such infections. They may either kill or inhibit the augmentation of bacteria. A limited number of antibiotics also acquire antiprotozoal activity. Antibiotics are not adequate against viruses such as the general cold or influenza; drugs that inhibit viruses are termed antiviral drugs or antivirals rather than antibiotics.
A drug interaction is a change in the side effects of a drug caused by contemporary administration with food, beverage, supplement, or another drug. There are many causes of drug interactions. For example, one drug may change the pharmacokinetics of another. Alternately, drug interactions may result from competition for a single receptor or signaling pathway. The risk of drug-drug interaction increases with the number of drugs used. Over a third (36%) of the elderly in the U.S. regularly uses five or more medications or supplements, and 15% are at the potential risk of a significant drug-drug interaction.
List of Common Infections Treated with Antibiotics:
- Conjunctivitis (Pink Eye)
- Otitis Media (Ear Infection)
- Sexually Transmitted Diseases (STD’s)
- Skin or Soft Tissue Infection
- Streptococcal Pharyngitis (Strep Throat)
- Traveler’s diarrhea
- Upper Respiratory Tract Infection
- Urinary Tract Infection (UTI)
Track 7: Types of Antibiotics and importance
Most antibiotics fall into their individual antibiotic classes. An antibiotic class is a grouping of different drugs that have identical chemical and pharmacologic properties. Their chemical structures may look commensurate, and drugs within the same class may kill the same or related bacteria.
Antibiotics are generally classified based on their mechanism of action, chemical structure, or spectrum of activity. Most target bacterial functions or growth processes. Those target the bacteria cell (penicillins and cephalosporins) or the cell layer (polymyxins), or prevent with necessary bacterial enzymes (rifamycins, lipiarmycins, quinolones and sulfonamides) have bactericidal actions. Protein synthesis inhibitors (macrolides, lincosamides, and tetracyclines) are generally bacteriostatic (with the omission of bactericidal aminoglycosides). Further categorization is based on their target specificity. Narrow-spectrum antibiotics focus on specific types of bacteria (gram-negative or gram-positive), whereas antibiotics affect a wide range of bacteria. Following a 40-year break in discovering new types of antibacterial compounds, four new classes of antibiotics have been brought into clinical use in the late 2000s and early 2010s: cyclic lipopeptides (like as daptomycin), glycylcyclines (like as tigecycline), oxazolidinones (like as linezolid), and lipiarmycins (like as fidaxomicin).
Antibiotic resistance is increased by the dissipate and overuse of antibiotics, as well as poor infection prevention and control. Steps can be taken at all levels of society to decrease the impact and limit the spread of resistance.
To prevent and control the circulate of antibiotic resistance, individuals can:
- Only use antibiotics when recommended by a certified health professional.
- Never demand antibiotics if your health worker announces you don’t need them.
- Always follow your health worker’s guidance when using antibiotics.
- Never share or use leftover antibiotics.
- Prevent infections by frequently washing hands, making healthy food, avoiding close contact with sick people, practicing safer sex, and keeping vaccinations up to date.
- Prepare healthy food, following the WHO Five Keys to Safer Food (keep clean, separate organic and cooked, cook thoroughly, place food at secure temperatures, use safe water and organic materials) and prefer foods that have been produced without the use of antibiotics for growth promotion or disease prevention in healthy animals.
Resistance to antibiotics can be produced by four general mechanisms:
- The inactivation or modification of the antibiotic;
- An alteration in the aim site of the antibiotic that decreases its binding capacity;
- The adjustment of metabolic pathways to circumvent the antibiotic effect;
- The decreased intracellular antibiotic accumulation by decreasing permeability and/or increasing active efflux of the antibiotic.
Antibiotics have been tested for the treatment of autoimmune diseases for over fifty years, based on the premise that infections play a role in the initiation and propagation of these entities. The antibiotics market was valued at USD 39.8 million in 2015 and is expected to witness a CAGR of 4.0% over the forecast period. Increasing endeavors are being witnessed toward the improvement of advanced products. According to the data published by the Pew Charitable Trust, in March 2016, around 37 promising molecules were being examined within the U.S. market. The majorities of these are in phase II clinical trials and are anticipated to hit the market between 2018 - 2020. Furthermore, supportive government legislation, like the Generating Antibiotics Incentives Now (GAIN) Act is expected to expedite the approval process. GAIN Act has provisions that facilitate the development of therapy against antibiotic-resistant pathogens.
Antibiotic resistance plays an important and influence on one’s health as treating an antibiotic-resistant infection is difficult. The management of broad-spectrum and narrow-spectrum antibiotics by patients should be resolved after good consultation with a doctor. The unwanted usage of high doses also causes genetic mutation in bacteria leading to antibiotic resistance. It has been estimated that 700,000 to several million deaths result per year as the resistance is increasing globally as exposure to antibiotic drugs has increased in developing countries.
Antibiotics are medicines used to avoid and treat bacterial infections. Antibiotic resistance occurs when bacteria transform in response to the utilization of these medicines. Bacteria, not humans or animals, become antibiotic-resistant. These bacteria may infect humans and animals, and the infections they cause are harder to treat than those caused by non-resistant bacteria. Antibiotic resistance leads to higher medical costs, prolonged hospital stays, and expanded mortality. The world immediately needs to transform the way it prescribes and uses antibiotics. Even if new medicines are developed, without behavior transformed, antibiotic resistance will continue a major threat. Behavior transformations must also include actions to reduce the spread of infections through vaccination, hand washing, practicing safer sex, and good food hygiene.
Reasons for the comprehensive use of antibiotics in human medicine include:
- Increasing universal availability over time since the 1950s
- Uncontrolled sale in many low or middle-income countries, where they can be obtained over the counter without a prescription, potentially resulting in antibiotics being used when not indicated. This may result in the emergence of resistance in any remaining bacteria.
Other causes include:
- Antibiotic benefits in livestock feed at minor doses for improvement promotion is an accepted practice in many industrialized countries and are known to lead to increased levels of resistance.
- Releasing huge quantities of antibiotics into the environment during pharmaceutical manufacturing through incompetent wastewater treatment increases the risk that antibiotic-resistant strains will develop and extended.
- It is uncertain whether antibacterial in soaps and other products share to antibiotic resistance, but antibacterial soaps are discouraged for other reasons.
Antibiotic resistance invokes especially to the resistance to antibiotics that occurs in common bacteria that cause infection. The easy approach and capability of Antibiotics led to overuse in live-stock rising promotes bacteria to flourish resistance. This led to comprehensive problems with antibiotic resistance. World Health Organization (WHO) classified antimicrobial resistance as a serious hazard and no longer an indicator for the future. Antibiotic resistance is now among every part of the world and its stirring everyone irrespective of the age. When infections become resistant to first-line drugs, high costly therapies must be needed. A longer duration of illness and treatment, often in hospitals, increases health care costs as well as the financial burden on families and societies. To guidance prevent the improvement of current and future bacterial resistance, it is necessary to recommend antibiotics according to the principles of antimicrobial stewardship, like specifying antibiotics only when they are useful.
Track 12: Antibiotics in Different Industries
Antibiotics must be used accordingly in humans and animals because of both use share with the emergence, persistence, and escalation of resistant bacteria. Resistant bacteria in food- generating animals are of particular concern. Food animals play as a cause of resistant pathogens and resistance mechanisms that can directly or indirectly result in antibiotic-resistant infections in humans. Resistant bacteria may be conveyed to humans through the foods we eat. Some bacteria have turned resistant to higher than one sort of antibiotic, which accomplishes it more difficult to treat the infections they cause. Preserving the efficiency of antibiotic drugs is vital to cushioning human and animal health.
Track 13: Applications of Antibiotics
Choice of related antibiotics is currently based on individual patient need. Preservation of bacterial sensitivity needs perceptive of how antibiotics select resistance. ‘Ten commandments’ which might be considered carefully when a preference has to be made for antibiotic prescribing. The compelling importance of the fact that all healthcare personnel should take ownership of the need to specify accordingly and to practice effective infection control. A realization that antibiotics may not be competent for the tasks required of them and eventually, with widespread resistance, may be incapable of the task they do today.
In the prior, most drugs have been invented either by identifying the active ingredient from traditional remedies or by serendipitous discovery. A new access has been to recognize how disease and infection are controlled at the molecular and physiological level and to mark specific entities based on this knowledge. The process of drug discovery involves the identification of candidates, characterization, screening, synthesis, and assays for therapeutic efficacy. The growth of an existing drug molecule from an ordinary form to a novel delivery structure can significantly develop its performance in terms of patient compliance, efficacy, and safety. These days, drug delivery organizations are engaged in the improvement of numerous platform technologies to get ambitious advantages, extend patient life, and increase the market share of their products. Formerly a compound has displayed its value in these tests; it will begin the process of drug development prior to clinical trials.
New diseases are originating globally and old diseases are re-emerging as Infectious agents increase or spread, and changes occur in conservation, socio-economic conditions, and population patterns. Likewise, many diseases thought to be decently controlled appear to be developing a revival. In advanced countries, public health measures like excrement treatment, vaccination programs, sanitation and access to good medical care-including a wide range of antibiotics-have essentially disposed of historical diseases like tuberculosis, diphtheria and whooping cough.
There is a renewed interest in the antibiotic sector, which is evident from the most recent patents and investments. Bacterial vaccines and new antibiotic classes are achieving an exceptional amount of attention with several product candidates in clinical development. These new products are expected to change the outlook of the antibiotic sector to a large extent over the next 5 years. Several reports focus on anti-infective markets in general. This report, however, focuses absolutely on antibacterial, with a specific emphasis on the emerging problem of antibiotic resistance. It also includes a detailed analysis of the emerging technology trends, which give a clear picture of the future of the sector. This helps to provide regulatory authorities and industry strategists a better perspective on which to base their decisions. BCC Research published a report about this topic in 2002. Since then, the market has witnessed dramatic changes in terms of technology, investment, and regulatory trends, which are captured in this report.
Antibiotic overuse and misuse have led to a growing number of bacteria in humans, animals and the environment that are resistant to life-saving antimicrobial therapies. Urgent activity is needed to halt the progress of resistance, and to accelerate new treatments for bacterial infection. Research includes the epidemiology of both Gram-negative and Gram-positive infections, genetic mechanisms of resistance, evolution and transmission in the hospital setting, as well as the community, and antimicrobial stewardship.
Antimicrobials 2020 Market Analysis
The worldwide Antibiotics market is esteemed at $6,727.29 million in 2014 and is relied upon to develop at a CAGR of 13.03% in the vicinity of 2014 and 2019. Expanding sickness weight of irresistible maladies and expanded subsidizing for social insurance consumption are the essential development drivers for this market amid the conjecture time frame. The pharmaceuticals application fragment represented the biggest share of the Antimicrobials advertise in 2014; while the nourishment application portion is normal develop at the most astounding CAGR in the vicinity of 2014 and 2019 in the worldwide Antibiotics showcase. The global clinical antimicrobials market is projected to reach USD 5.77 Billion by 2021 from USD 3.35 Billion in 2016, growing at a CAGR of 11.5% from 2016 to 2021. Market growth can be attributed to factors such as the technological advancements; rising incidence of infectious diseases and growing outbreak of epidemics; growing healthcare expenditure across the world; and increasing funding, research grants, and public-private investments in the field of life science researches.
Emerging regions such as Asia-Pacific (including Japan, China, and India) are expected to become the new revenue-generating pockets in the market in the next five years. The Asia-Pacific market is projected to grow at the highest CAGR during the forecast period owing to the growing number of hospitals and clinical diagnostic laboratories in India and China; expanding research capabilities for the development of innovative and affordable clinical Antibiotics testing procedures across India, China, and Japan; and rising incidences of infectious diseases.
Market research is vital to the development of the industrial market, and continues to be in demand. In 2018, we anticipate delivery of new editions of our report on Antimicrobials Testing in the Global spurt.
Global Market Survey:
Antimicrobials size was valued at over USD 24.3 billion in 2017 and will exceed USD 675.2 billion with 7.9% CAGR from 2017 to 2024. At Global Market Insights, It is a unique blend of primary and secondary research, with validation and iterations, in order to minimize deviation and present the most accurate analysis of the industry.
Rising demand of new technologies will drive the biotechnology industry size. we’ve seen tremendous growth and change in the industrial diagnostics industry, particularly in the food safety sector expertise in all aspects of the market, plus extensive experience in business management, strategy development and international business, Antibiotics test volumes, market values and methods used by food producers around the world, based on detailed interviews with more than 450 food production facilities in America, Europe and Asia, including Japan. Total test volumes have increased 128%, and testing for specific foodborne pathogens like Salmonella and E. coli grew at an even faster rate.
The global DNA sequencing market is projected to reach USD 85.5 Million by 2025 from USD 310.1 Million in 2017 growing at a CAGR of 8.5% during the forecast period.
The global market for Food Antibiotics reached nearly $7.1 billion in 2017. This market is expected to grow to nearly $9.6 billion in 2017 and $15.7 billion by 2025, with a compound annual growth rate (CAGR) of 8.1% from 2017 to 2025.
Global Nanotechnology Market was valued at $216.2 billion in 2017 and $448.3 billion in 2017. The total market is projected to grow at a compound annual growth rate (CAGR) of 19.3% from 2017 through 2025 and reach $828 billion by 2025.
Based on technology, the industry is segmented into tissue engineering and regeneration, fermentation, PCR, nanotechnology, chromatography, DNA sequencing and cell based assay. In 2017, the tissue engineering and regeneration segment accounted for highest revenue and was valued at over USD 11.3 billion. However, the nanotechnology, fermentation and cell based assay segments will experience lucrative growth owing to rising R&D initiatives by various biotechnological and pharmaceutical companies.
The global clinical Antimicrobials market is valued at $6,727.29 million in 2014 and is expected to grow at a CAGR of 13.03% between 2014 and 2019. Increasing disease burden of infectious diseases and increased funding for healthcare expenditure are the important growth drivers for this market during the forecast period. The pharmaceuticals application segment accounted for the largest share of the Antibiotics market in 2014, while the food application segment is expected grow at the highest CAGR between 2014 and 2019 in the global Antimicrobials market.
Several microorganisms are used in industrial Antibiotics, including laboratory-selected mutants, naturally occurring organisms, and genetically modified organisms (GMOs). Antimicrobials research and development is finding increasing application in oil and gas organizations, the food and beverage industry, and environmental testing organizations.
In addition, the traditional R&D in the biopharmaceutical industry is witnessing an upsurge, due to drug development research, which is helping in the augmentation of the industrial Antibiotics market.
Increased demand for nutraceuticals and other fermented products further drives the importance of industrial application of Antimicrobials on a large scale. Such factors are helpful to drive the industrial market.
However, in the market, there are several conflicts observed regarding the usage of genetically modified organisms in food sources, which are expected to restrict the growth of the industrial Antibiotics market.
Past Conference Report
The 7th World Congress on Antibiotics, Antimicrobials & Antibiotic Resistance, (Antimicrobials 2019) was held in Tokyo, Japan during May 20-21, 2019.
Antimicrobials 2019 has welcomed the new era of Antibiotics & Antimicrobials; a futuristic arena for treatment of diseases, clasping a promising tomorrow. The highly exalted conference hosted by Conference Series LLC ltd was marked with the attendance of young and brilliant researchers, business delegates and talented student communities representing more than 20 countries around the world. The conference has tried grounding every aspect related to Antibiotics & Antimicrobials, covering all the possible research areas.
The conference aimed a parallel rail with theme “Antibiotics: Discovery, Resistance, and Alternatives”. The meeting engrossed a vicinity of cognizant discussions on novel subjects like Antibiotics: an overview, Antibiotic resistance in a one-health context, Microbial virulence, Developing new drugs: academic and industrial innovations, Antibiotics, microbes and models, Antibiotics by chemical class to mention a few.
Conference Series extends its warm gratitude towards all the Participants, Eminent Speakers, Young Researchers, Delegates and Students.
We would like to specially thank the following people who laid the foundation for the event’s success.
Organizing Committee Members:
Bernhard R. Ruf - Klinikum St. Georg gGmbH, Germany
Tadashi Shimamoto - Hiroshima University, Japan
Martin Duerden - Bangor University, UK
Yasuhiro Igarashi - Toyama Prefectural University, Japan
Lidia Sas Paszt, Research Institute of Horticulture, Poland
Tadashi Shimamoto, Hiroshima University, Japan
Stef Stienstra, Dutch Armed Forces/Royal Dutch Navy, Netherlands
Ewa Solarska, University of Life Sciences in Lublin, Poland
Maulin P Shah, Enviro Technology Limited, India
Clarence M Ongkudon, University Malaysia Sabah, Malaysia
Marina Sidorenko, Federal Scientific Center of the East Asia Terrestrial Biodiversity, Russia
Mohammad Magdy El Metwally, Damanhour University, Egypt
After the huge optimistic response from the scientific fraternity, renowned personalities and the Editorial Board Members of Conference Series from across the world. We are pleased to announce the 8th World Congress on Antibiotics, Antimicrobials & Antibiotic Resistance to be held during May 26-27, 2020 at Singapore.
Let us meet again @ Antimicrobials 2020
Past Reports Gallery